NKG2A & CD94 Overview
Molecule Name
NK cell lectin-like receptor subfamily C member 1
Synonyms
NKG2A & CD94
Drug Development Progress
Drugs in Clinical Trials6
Approved Drugs0
Highest Development StagePhase 3 Clinical
Target Synonym
CD159a，NKG2A，KLRC1，Killer Cell Lectin Like Receptor C1，Killer Cell Lectin-Like Receptor Subfamily C， Member 1，CD159 Antigen-Like Family Member A，NKG2-1/B Activating NK Receptor，NKG2-A/B-Activating NK Receptor，NK Cell Receptor A，NKG2-A/NKG2-B Type II Integral Membrane Protein，NKG2-A/B Type II Integral Membrane Protein，Natural Killer Group Protein 2，Natural Killer Cell Lectin，C-Lectin Type II Protein，CD159a Antigen，NKG2，NKG2-B，NKG2-A
Background
CD94 plays a role as a receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells. KLRD1 (CD94) is an antigen preferentially expressed on NK cells and is classified as a type II membrane protein because it has an external C terminus. NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation. CD94 pairs with the NKG2 molecule as a heterodimer. The CD94/NKG2 complex, on the surface of natural killer cells interacts with Human Leukocyte Antigen (HLA)-E on target cells.
NKG2A & CD94 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Monalizumab | NNC-0141-0000-0100; NNC 0141-0000-0100; IPH-22XX; IPH-22; NN-8765; IPH-2201 | Phase 3 Clinical | Novo Nordisk A/S | Arthritis, Rheumatoid; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Genital Neoplasms, Female; Head and Neck Neoplasms; Hematologic Neoplasms; Inflammation; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Oral Squamous Cell Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
| BMS-986315 | BMS-986315 | Phase 2 Clinical | Bristol-Myers Squibb Company | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| S-095029 | S-095029 | Phase 2 Clinical | Institut De Recherches Internationales Servier | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Solid tumours; Stomach Neoplasms | Details |
| HY000102 | HY-0102; HY-000102 | Phase 2 Clinical | Shanghai HyaMab Biotech Co Ltd | Pancreatic Neoplasms; Solid tumours | Details |
| XB-628 | XB628 | Phase 1 Clinical | Exelixis Inc | Neoplasms; Solid tumours | Details |
| BRY-805 | BRY805; BRY-805 | Phase 1 Clinical | Hisun Biopharmaceutical Co Ltd, Zhejiang BioRay Biopharmaceuticals Co Ltd | Solid tumours | Details |